Platform biotech describes a life-sciences company whose core value is a repeatable scientific or technical capability—CRISPR tooling, antibody discovery, targeted delivery—that can spawn multiple therapeutic programs or licensing deals.

How it works

Asset biotech centers on one lead molecule moving through clinical stages. Platform biotech centers on proof that the underlying method works across indications or partners. Revenue may come from internal pipeline milestones, collaboration upfronts, and royalties—not only from a single FDA approval.

VC diligence asks: Does data from program A predict success in program B? Are IP and manufacturing scalable? Platform companies often raise larger rounds because burn includes parallel experiments, but exit paths include pharma partnerships early if the engine is credible.

Why it matters

• Founders: Pitch the platform with concrete program maps and partnership logic—not abstract “AI for biology” without validated outputs.
• Investors: Platform premium depends on reproducibility. One lucky clinical readout does not prove a platform without orthogonal validation.

Common mistake

Labeling a single-asset biotech a “platform” because it uses common lab techniques. Investors distinguish proprietary, defensible engines from commodity methods.

Related ideas

See platform company, patent portfolio, and pipeline strategy in life sciences.